Glenn Saldanha, chairman and managing director of Glenmark Pharma, tells NDTV Profit that the company's Indian business has been robust in terms of growth in the quarter ended June. Indicating why US business revenues have been flat, he also briefs us on Glenmark's current new chemical entity (NCE) entries in the pipeline.
